Joint Disease Pathology — OA and RA

OSTEOARTHRITIS: DEGENERATIVE JOINT DISEASE

• Cartilage Degradation Cascade: OA involves progressive loss of articular cartilage through imbalance between anabolic and catabolic processes. Mechanical stress and aging trigger increased expression of matrix metalloproteinases (MMPs, especially MMP-1, MMP-3, MMP-13) and aggrecanases (ADAMTS-4, ADAMTS-5) by chondrocytes. These enzymes cleave collagen type II and proteoglycan core proteins (aggrecan), leading to loss of cartilage matrix integrity. Concurrently, production of proteoglycans and collagen decreases, tipping the balance toward net matrix loss. Reactive oxygen species (ROS) generated from mitochondrial dysfunction amplify chondrocyte apoptosis and further suppress anabolic signaling.

• Inflammatory Microenvironment in OA: Contrary to historical perception as purely "non-inflammatory," OA involves low-grade chronic inflammation. Cartilage fragments and damage-associated molecular patterns (DAMPs) like high-mobility group box 1 (HMGB1) and hyaluronic acid oligomers activate synovial macrophages and lining cells via pattern recognition receptors (TLRs, NLRP3 inflammasome). This triggers production of IL-1β, TNF-α, IL-6, and IL-8, which perpetuate chondrocyte degradation and recruit additional immune cells. Synovial fluid accumulation and joint effusion reflect this inflammatory state.

• Bone Remodeling and Osteophyte Formation: Subchondral bone undergoes pathological remodeling with increased osteoclast activity early, causing bone loss and microfractures, followed by excessive osteoblast activity producing sclerotic bone and osteophytes (bone spurs). These marginal osteophytes represent an attempted repair response but contribute to joint dysfunction and mechanical symptoms. Subchondral bone cysts form from intrusion of synovial fluid through cartilage-bone interface defects. Sclerosis of subchondral bone increases stiffness, transmitting greater loads to remaining cartilage and accelerating degeneration.

RHEUMATOID ARTHRITIS: AUTOIMMUNE SYNOVITIS

• Autoimmune Initiation and Perpetuation: RA is initiated by loss of immune tolerance to self-antigens, particularly in genetically predisposed individuals (HLA-DR4/DR1 "shared epitope"). Anti-citrullinated protein antibodies (anti-CCP) and rheumatoid factor (RF) form immune complexes that deposit in synovium and joint capsule, activating complement cascade (C5a generation) and recruiting neutrophils and macrophages. These autoantibodies precede clinical disease, identifying a preclinical phase. Genetic susceptibility (HLA-DRB1 alleles, PTPN22, STAT4 polymorphisms) combined with environmental triggers (smoking, infection with Porphyromonas gingivalis, molecular mimicry) breach tolerance through aberrant Th17 and Tfh cell responses.

• Synovial Inflammation and Pannus Formation: The RA synovium transforms into a hyperplastic, highly inflammatory tissue dominated by CD4+ T cells, B cells, plasma cells, macrophages, and fibroblasts. These cells produce pro-inflammatory cytokines including TNF-α, IL-1β, IL-6, IL-17, and GM-CSF, creating a self-perpetuating inflammatory loop. Fibroblast-like synovial cells (FLS) become activated and invasive, producing additional cytokines, MMPs, and receptor activator of NF-κB ligand (RANKL), driving osteoclastogenesis. The proliferating synovium develops into pannus tissue — a vascular, inflammatory, invasive tissue that erodes cartilage and bone at the cartilage-pannus interface and marrow space.

• Osteoclast Activation and Bone Destruction: In RA, osteoclasts are activated directly by RANKL (expressed on activated T cells and FLS) and by TNF-α and IL-1β, which bypass RANKL signaling. This leads to periarticular osteopenia early (loss of cortical and trabecular bone around joints) and later erosive bone destruction visible on radiographs as marginal erosions at cartilage-pannus junction. Paradoxically, systemic osteoporosis develops due to systemic TNF-α, IL-6, and reduced OPG production, making RA patients susceptible to fractures despite bone density considerations.

• B Cell and Antibody-Mediated Pathology: Autoreactive B cells undergo somatic hypermutation in synovial germinal center-like structures, producing high-affinity anti-CCP, anti-CCP/IgG immune complexes deposit in synovium and glomeruli (secondary renal disease), activate complement, and directly activate macrophages via Fc receptors. Some synovial B cells differentiate into plasma cells, maintaining chronic antibody production. Anti-CCP positivity predicts erosive disease and poor prognosis.

OSTEOARTHRITIS

• Primary (Idiopathic) OA: Advanced age, female sex (particularly post-menopausal), obesity (mechanical stress and adipokine-induced inflammation), prior joint trauma or meniscectomy, repetitive use/occupational stress, genetic predisposition (COL2A1 mutations, FRZB, ASPM polymorphisms), joint malalignment (varus/valgus deformity).

• Secondary OA: Avascular necrosis, hemochromatosis (iron deposition in cartilage), Wilson's disease (copper accumulation), alkaptonuria (ochronotic arthropathy), acromegaly, Paget's disease, gout (calcium pyrophosphate deposition disease), prior inflammatory arthritis, metabolic syndrome, estrogen deficiency.

• Risk Factors: Age >50 years, female sex, BMI >30, joint injury, muscle weakness (particularly quadriceps weakness increases knee OA risk), joint hypermobility.

RHEUMATOID ARTHRITIS

• Genetic Susceptibility: HLA-DRB1 alleles encoding "shared epitope" (particularly *0401, *0404, *0101) confer 3-5 fold increased risk; accounts for ~50% of genetic risk. Non-HLA genes: PTPN22 (lymphoid tyrosine phosphatase), STAT4, TRAF1/C5, IL2RA, IL2RB, IL6R.

• Environmental Triggers: Cigarette smoking (2-3 fold increase, dose-dependent; impairs Foxp3+ regulatory T cells and enhances anti-CCP production); Porphyromonas gingivalis (periodontitis, shares epitope with CCP); Epstein-Barr virus (mimicry); female sex (2-3:1 female predominance, hormonal factors), pregnancy (paradoxical improvement during pregnancy due to Th2 shift and IL-10 production; postpartum flare common), early menarche, nulliparity, short duration of breastfeeding.

• Dual Positivity Risk: Patients positive for both RF and anti-CCP have highest risk of erosive, aggressive disease; anti-CCP positivity alone predicts development of RA in seronegative individuals.

OSTEOARTHRITIS

• Mechanical Pain: Deep aching pain worse with activity and weight-bearing (morning stiffness <30 minutes, relieved by rest); night pain from joint effusion and intra-articular inflammation. Pain correlates with cartilage loss on imaging but not always with symptoms (poor anatomic-clinical correlation).

• Physical Examination Findings:
• Crepitus (coarse, audible grinding from irregular articular surface) on passive/active motion
• Bony enlargement with Heberden nodes (DIP joint osteophytes) and Bouchard nodes (PIP joint osteophytes) in hand OA
• Joint line tenderness over affected cartilage
• Decreased range of motion from capsular fibrosis and osteophytes
• Joint effusion (bulging joint capsule, fluid wave in knee)
• No systemic findings (afebrile, no rash, normal vitals)

• Imaging and Lab Correlates:
• Radiographic hallmarks: Joint space narrowing (cartilage loss), osteophytes at joint margins, subchondral sclerosis (increased bone density), subchondral cysts
• Mild synovial fluid inflammation (WBC <2,000/μL, predominantly mononuclear)
• Normal to mildly elevated inflammatory markers (ESR, CRP usually normal or minimally elevated)
• Negative or low-titer rheumatoid factor and anti-CCP (seronegative)

• Progression Pattern: Insidious onset in middle-aged/elderly; slowly progressive over years to decades; affects weight-bearing joints (knees, hips) and hand joints (DIP > PIP > MCP); morning stiffness improves with activity (unlike RA).

RHEUMATOID ARTHRITIS

• Polyarticular Symmetric Joint Pain and Swelling: Acute or insidious onset of symmetric pain, swelling, and warmth in small joints of hands (MCP, PIP) and feet (MTP), often with systemic prodrome (fatigue, malaise, low-grade fever). Morning stiffness >1 hour (vs. OA <30 min) is cardinal, reflecting synovial inflammation; improves with activity. Pain worse after rest and improves with continued movement.

• Physical Examination Findings:
• Tender, boggy, warm joints with fusiform (spindle) swelling of fingers (symmetric periarticular soft tissue edema)
• Ulnar deviation of fingers and swan neck deformity (PIP hyperextension, DIP flexion) from ligament laxity and tendon rupture in established disease
• Boutonnière deformity (PIP flexion, DIP extension)
• Z-thumb deformity (CMC flexion, IP extension)
• Positive squeeze test of metatarsal heads (metatarsalgia)
• Decreased grip strength (objective functional impairment)
• Joint line tenderness and effusions, but no crepitus (cartilage intact early)

• Systemic Manifestations:
• Rheumatoid nodules (firm, non-tender subcutaneous nodules over pressure points: extensor surfaces of elbows, fingers, Achilles tendons) in 20-30% RF+ patients; pathology shows central fibrinoid necrosis surrounded by palisading histiocytes and fibroblasts
• Constitutional symptoms: fever, weight loss, fatigue from chronic inflammation
• Extra-articular manifestations: rheumatoid vasculitis (small vessel), pleural effusions, pericarditis, pulmonary nodules/ILD, secondary Sjögren syndrome, keratitis sicca, scleritis

• Lab and Imaging Correlates:
• Elevated inflammatory markers: ESR >40 mm/hr, elevated CRP (>10 mg/L), indicating active synovitis
• Positive RF (>1:80 titer, IgM/IgG) in ~80% early; present in preclinical phase
• Positive anti-CCP (>20 AU/mL) in ~70% and more specific than RF; present years before clinical disease; predicts erosive disease
• Mild normocytic anemia from chronic inflammation (anemia of chronic disease) and marrow suppression
• Synovial fluid: inflammatory fluid with WBC 2,000-50,000/μL, predominantly neutrophils (>50%), low viscosity, poor mucin clot, negative cultures and crystals
• Radiographic changes evolve: early (soft tissue swelling, periarticular osteopenia, normal joint space); established (uniform joint space narrowing, marginal erosions at cartilage-pannus junction, subluxation); late (complete joint destruction, ankylosis)

OSTEOARTHRITIS

• Histological Features:
• Early changes: Surface fibrillation and vertical clefting of articular cartilage ("fibrillation"), slight chondrocyte clustering (chondrone formation — groups of chondrocytes surrounding lacunae)
• Progressive changes: Partial-thickness cartilage loss with exposed bone, irregular articular surface, chondrocyte death (empty lacunae), increased vascularity at cartilage-bone interface
• Advanced changes: Complete cartilage denudation exposing sclerotic subchondral bone ("eburnation"), dense fibrous tissue replacement, peripheral osteophytes with cartilage cap
• Synovial histology: Villous hypertrophy, mild lymphocytic infiltration, lining cell hyperplasia, minimal to mild inflammation (not diagnostic)

• Gross Pathology Appearance:
• Eburnated bone — polished, ivory-like exposed bone from cartilage loss
• Marginal osteophytes — bony ridges at joint margins
• Fibrillated, yellowed cartilage with clefts and irregular surface
• Shiny, sclerotic subchondral bone with cystic cavities

• Diagnostic Criteria (Clinical and Radiographic — No Lab Tests Diagnostic):
• ACR Clinical Criteria for Knee OA: Knee pain >50% days/month + at least 2 of: age >50, morning stiffness <30 min, crepitus on motion
• ACR Radiographic Criteria: Osteophytes at tibiofemoral joint + at least one of: age >50, morning stiffness <30 min, crepitus
• Hand OA criteria: Cartilage loss and osteophytes on imaging + morning stiffness <30 min + age >40

• Imaging (Radiographs, MRI, Ultrasound):
• Plain radiographs (standing views): Joint space narrowing, osteophytes, subchondral sclerosis, cyst formation (late)
• MRI: Shows early cartilage thinning/softening before radiographic changes; synovial inflammation, effusion, bone marrow edema in adjacent bone
• Ultrasound: Cartilage thinning, osteophytes, synovial effusion, anechoic bands in cartilage

• Laboratory Tests: Primarily negative or normal (helps exclude RA):
• RF and anti-CCP negative (or very low titer)
• ESR and CRP normal or mildly elevated
• Synovial fluid: non-inflammatory (<2,000 WBC/μL), negative cultures/crystals (unless secondary cause)

RHEUMATOID ARTHRITIS

• Histological Features (Synovial Biopsy — Not Routine, but Diagnostic):
• Hyperplastic synovium with villous projections and increased surface area
• Dense lymphoid infiltration with germinal center-like structures (B cells, T cells, plasma cells, macrophages); CD4+ T cells predominate (Th1, Th17 subsets)
• Synovial lining cell hyperplasia (1-2 layers to 10+ layers thick) with increased fibroblast-like and macrophage-like cells
• Fibrin deposition on synovial surface and vessel walls

Immediate concerns before chronic therapy

• Exclude septic arthritis: a single hot, disproportionately swollen joint in a patient with known OA or RA demands arthrocentesis before any steroid injection or DMARD escalation — intra-articular glucocorticoid into an infected joint is catastrophic.

Osteoarthritis — ACR/Arthritis Foundation 2019 guideline

• Non-pharmacologic core therapy (strongly recommended): structured exercise, weight loss in overweight patients (reduces joint loading and adipokine-driven inflammation), and knee bracing/cane for offloading. This is first-line, not adjunctive.
• Topical NSAIDs (e.g., diclofenac gel): strongly recommended first-line pharmacotherapy for knee OA — high local, low systemic exposure, preferred in elderly and CKD.
• Oral NSAIDs (e.g., naproxen) at the lowest effective dose; acetaminophen and duloxetine are conditionally recommended adjuncts.
• Intra-articular glucocorticoid (e.g., triamcinolone) for flares; effect is short-lived and repeated injections risk cartilage loss.
• Definitive: total joint arthroplasty for end-stage disease with refractory pain and functional loss.
• Recommended against: glucosamine/chondroitin, bisphosphonates, hydroxychloroquine, methotrexate, and TNF inhibitors for OA; opioids are discouraged; hyaluronic acid injection is recommended against in the hip.

Rheumatoid arthritis — ACR 2021 guideline, treat-to-target

• Methotrexate monotherapy is first-line for DMARD-naive moderate-to-high disease activity; always co-prescribe folic acid to limit mucositis and cytopenias. Hydroxychloroquine or sulfasalazine may suffice in low disease activity.
• Bridging glucocorticoids (prednisone) control symptoms while DMARDs take effect; ACR advises against prolonged low-dose steroid maintenance.
• Escalation if target (remission/low disease activity) not met: add a TNF inhibitor (adalimumab), a non-TNF biologic (abatacept, tocilizumab, rituximab), or a JAK inhibitor (tofacitinib). Screen for latent TB and hepatitis B before biologics.
• Contraindicated: methotrexate and leflunomide in pregnancy (teratogenic — use hydroxychloroquine or sulfasalazine); TNF inhibitors in active infection, untreated latent TB, demyelinating disease, and advanced heart failure. JAK inhibitors carry an FDA boxed warning for thrombosis, MACE, and malignancy.
• Surgical: synovectomy, tendon repair, arthroplasty for destroyed joints; cervical fusion for atlantoaxial instability.

Disease complications — osteoarthritis

• Progressive functional loss and falls: cartilage loss plus quadriceps deconditioning; signaled by declining gait speed and inability to rise from a chair.
• Baker (popliteal) cyst rupture: effusion decompresses posteriorly, then dissects into the calf producing pseudothrombophlebitis — calf pain and crescent-shaped ecchymosis below the malleolus; ultrasound distinguishes it from DVT.
• Secondary CPPD and spinal stenosis: facet and ligamentum flavum hypertrophy produce neurogenic claudication relieved by lumbar flexion.

Disease complications — rheumatoid arthritis

• Atlantoaxial subluxation (emergency): pannus erodes the transverse ligament and dens, allowing C1–C2 slip and cord compression — neck pain with occipital radiation, hyperreflexia, Lhermitte phenomenon. Obtain flexion–extension cervical films before any intubation.
• Cricoarytenoid arthritis (emergency): hoarseness progressing to stridor and airway obstruction.
• Septic arthritis (emergency): damaged synovium plus immunosuppression; a single joint flaring out of proportion — arthrocentesis immediately.
• Accelerated atherosclerosis: chronic IL-6/TNF-driven endothelial injury; cardiovascular disease is the leading cause of death in RA.
• Interstitial lung disease and Caplan syndrome: dyspnea with basilar crackles; Caplan = RA plus pneumoconiosis with upper-lobe nodules.
• Felty syndrome: RA + splenomegaly + neutropenia → recurrent bacterial infection and leg ulcers.
• Rheumatoid vasculitis: nailfold infarcts, mononeuritis multiplex, digital gangrene.
• Secondary AA amyloidosis: chronic serum amyloid A elevation → proteinuria/nephrotic syndrome; apple-green birefringence on Congo red.

Treatment complications

• Methotrexate: hepatotoxicity (rising transaminases), myelosuppression, mucositis, and acute pneumonitis (emergency) — new dry cough, hypoxemia, diffuse infiltrates; stop the drug.
• TNF inhibitors: reactivation of latent tuberculosis (often disseminated/miliary), histoplasmosis, hepatitis B reactivation.
• Rituximab: hypogammaglobulinemia, HBV reactivation, rare PML.
• Tocilizumab: blunts CRP and fever, masking infection; GI perforation risk in diverticular disease.
• NSAIDs: peptic ulcer bleeding, AKI from prostaglandin-dependent afferent vasodilation loss, hypertension.
• Glucocorticoids: osteoporotic fracture, osteonecrosis, hyperglycemia.
• Arthroplasty: periprosthetic joint infection, VTE, aseptic loosening.

• Joint distribution is the discriminator: DIP involvement with Heberden nodes = OA; MCP, PIP, and wrist involvement with DIP sparing = RA. A stem describing DIP nodules and no morning stiffness is not RA no matter how many joints are involved.
• Stiffness clock: morning stiffness >1 hour improving with use = inflammatory (RA); <30 minutes worsening with use = mechanical (OA).
• Radiographic signature: OA gives asymmetric/focal joint space narrowing, osteophytes, subchondral sclerosis and cysts; RA gives uniform joint space narrowing, periarticular osteopenia, and marginal erosions at the cartilage–pannus junction. Osteophytes and sclerosis are not RA findings.
• Anti-CCP is the specificity antibody: RF is more sensitive but also positive in hepatitis C, Sjögren, endocarditis, and healthy elderly. Anti-CCP predicts erosive disease and appears years before symptoms. Dual RF/anti-CCP positivity plus smoking is the classic aggressive-disease vignette.
• Single best next step for a hot joint: arthrocentesis with cell count, Gram stain, culture, and crystal analysis — before steroids, before escalating DMARDs. A joint flaring out of proportion in an immunosuppressed RA patient is septic until proven otherwise.
• The association examiners love: RA and atlantoaxial subluxation. Before elective surgery or intubation, get flexion–extension cervical spine radiographs; missing it risks cord transection.
• Methotrexate is the RA anchor drug (ACR 2021) — first-line, with folic acid, and absolutely contraindicated in pregnancy. In a pregnant RA patient, hydroxychloroquine or sulfasalazine is the answer.
• Common distractors: don't screen for TB after starting a TNF inhibitor — do it before; don't treat OA with methotrexate, TNF inhibitors, or glucosamine (ACR 2019 recommends against all three); and remember RA symptoms often improve during pregnancy with a postpartum flare.